CryoPop研究:印度卡纳塔克邦高级别宫颈异型增生的筛查
该前瞻性队列研究在印度三个地区对30-49岁女性用醋酸白试验(VIA)筛查宫颈高级别病变,2020年7月4日至2021年3月31日共筛查9130人,VIA阳性501人(5.5%),其中401人接受阴道镜,活检发现17人(4.2%)为高级别病变。作者认为VIA主观性强、准确性不足,在低患病率人群中可能不够可靠。
要点
- 9130名女性接受VIA筛查,501人(5.5%)VIA阳性,其中401人接受阴道镜。
- 阴道镜活检发现17人(4.2%)高级别病变,164人(40.9%)低级别病变,1人(0.2%)浸润癌。
- VIA阳性者更年轻、受教育程度和收入更高;活检CIN2/3者年龄更大、更多为家庭主妇、家庭收入更高。
核心结论
- 尽管有COVID-19疫情,仍有超过9100名女性接受VIA筛查,但仅17人(4.2%)活检证实高级别宫颈病变,凸显VIA作为筛查方法的主观性。
- 该比例显著低于文献报告,可能因筛查人群较年轻且更偏农村,影响了高级别病变的患病率。
- 研究表明有组织筛查可行且能快速扩大,但VIA可能过于主观且准确性不足,难以明确识别需要治疗的病变,尤其在低患病率和低风险人群中,对其总体成本效益提出疑问。
研究设计与样本
- 前瞻性队列研究,在印度Belagavi、Hubballi和Vijayapur的初级和城市卫生中心开展。
- 筛查对象为30-49岁、绝经前、无子宫切除史且无已知HIV感染的女性。
- 对符合条件女性行VIA,VIA阳性者转诊阴道镜和活检;活检由两名病理学家独立阅片,必要时第三名病理学家仲裁。
- 主要结局为VIA筛查阳性的人数/比例及VIA阳性者活检发现高级别宫颈病变(CIN2/3)的人数/比例。
主要发现
- 2020年7月4日至2021年3月31日共9130名女性接受VIA筛查,平均年龄37岁(标准差5.6岁),6073人(66.5%)在30-39岁范围。
- 仅1%的女性报告既往接受过宫颈癌筛查。
- 501名女性(5.5%)VIA阳性,其中401人接受阴道镜。
- 接受阴道镜者中,17人(4.2%)活检为高级别病变,164人(40.9%)活检或宫颈管刮取为低级别宫颈病变,1人(0.2%)为浸润癌。
- VIA阳性女性更年轻、受教育程度和收入更高;VIA阳性且活检CIN2/3的女性比无CIN2/3者年龄更大、更多为家庭主妇、家庭收入更高。
关键数值与推荐
- VIA筛查阳性定义为醋酸白试验阳性,阳性者转诊阴道镜和活检。
- 高级别病变定义为活检证实的宫颈上皮内瘤变2/3(CIN2/3)。
- 统计分析使用卡方或Fisher精确检验(分类变量)及t检验或方差分析(数值变量),所有检验双侧,显著性水平α=0.05。
临床怎么用
- 作者认为VIA筛查可在有组织的方式下可行且快速扩大,但VIA可能过于主观且准确性不足,难以明确识别需要治疗的病变。
- 作者认为在低患病率和低风险人群中,VIA的总体成本效益存疑。
局限性
- 作者指出仅17人(4.2%)活检证实高级别病变,可能因筛查人群较年轻且更偏农村而影响患病率。
- 作者认为VIA可能过于主观且准确性不足,尤其在低患病率和低风险人群中,对其总体成本效益提出疑问。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe our experience of screening with visual inspection with acetic acid (VIA) and colposcopy to identify women with high-grade precancerous cervical lesions who were candidates for cryotherapy. Women were screened to determine eligibility for a clinical trial testing the safety and efficacy of a new, simple and inexpensive cryotherapy device (CryoPop®) targeted for use in low and middle-income countries (LMICs). DESIGN: Prospective cohort study. SETTING: Primary and urban health centres in Belagavi, Hubballi and Vijayapur, India. POPULATION: Women in the age-group 30-49 years, premenopausal, with no prior hysterectomy and no known HIV infection were eligible for screening. METHODS: Visual inspection with acetic acid was performed on eligible women following informed consent. VIA-positive women were referred for colposcopy and biopsy. Biopsies were read by two pathologists independently, with a third pathologist acting as tie-breaker if needed. MAIN OUTCOME MEASURES: The primary outcome measures were the number/proportion of women screening positive by VIA and the number/proportion of those women screening VIA-positive found to have high-grade cervical lesions on biopsy (cervical intraepithelial neoplasia 2/3 [CIN 2/3]). Demographic variables were compared between women who screened VIA-positive and those who screened VIA-negative; a separate comparison of demographic and limited reproductive variables was performed between women who had CIN 2/3 on biopsy and those without CIN 2/3 on biopsy. Chi-square or Fisher's exact tests for categorical data and t-tests or analysis of variance for numeric data were used with all tests two-sided and performed at an alpha 0.05 level of statistical significance. RESULTS: A total of 9130 women were screened with VIA between 4 July 2020 and 31 March 2021. The mean age of all women screened was 37 years (standard deviation = 5.6 years) with 6073 of the women (66.5%) in the 30-39 year range. Only 1% of women reported prior cervical cancer screening. A total of 501 women (5.5%) were VIA-positive; of these, 401 women underwent colposcopy. Of those who had colposcopy, 17 (4.2%) had high-grade lesions on biopsy, an additional 164 (40.9%) had low-grade cervical lesions on biopsy or endocervical curettage and one woman (0.2%) was found to have invasive cancer. VIA-positive women were younger and had higher levels of education and income; however, women who were VIA-positive and found to have CIN 2/3 were older, were more likely to be housewives and had higher household income than those without CIN 2/3. CONCLUSION: Despite the COVID-19 pandemic, over 9100 women were screened with VIA for precancerous lesions. However, only 17 (4.2%) were found to have biopsy-proven high-grade cervical lesions, underscoring the subjective performance of VIA as a screening method. Given that this is significantly lower than rates reported in the literature, it is possible that the prevalence of high-grade lesions in this population was impacted by screening a younger and more rural population. This study demonstrates that screening is feasible in an organised fashion and can be scaled up rapidly. However, while inexpensive and allowing for same-day treatment, VIA may be too subjective and have insufficient accuracy clearly to identify lesions requiring treatment, particularly in low-prevalence and low-risk populations, calling into question its overall cost-effectiveness.
引用
- Anderson JR, Yogeshkumar S, Lu E, et al. The CryoPop study: Screening for high-grade cervical dysplasia in Karnataka, India. BJOG. 2023. PMID: 37932903. doi:10.1111/1471-0528.17702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。